Colorectal Tumor: Clinical Trials

3 trials for Colorectal Tumor, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 1 recruiting. 3 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 23Completed 2, Recruiting 1
Phase 11Completed 1

Follow Colorectal Tumor: new trials by email Literature Review of Colorectal Tumor trials Research Report on Colorectal Tumor

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab.
encorafenib + cetuximab + FOLFIRI - Colorectal Carcinoma, Colorectal Neoplasms
Phase 2RecruitingFondazione Policlinico Universitario Agostino Gemelli IRCCS252024-06-032025-02-12
A Study of Irinotecan Plus Cetuximab With or Without Enzastaurin in Participants With Colorectal Cancer
enzastaurin, irinotecan, cetuximab - Colorectal Cancer, Colorectal Carcinoma
Phase 2CompletedEli Lilly and Company262007-03-012020-07-21
Safety Study of 90Y-hMN14 to Treat Colorectal Cancer
hMN14 (labetuzumab) - Colorectal Cancer, Colon Cancer
Phase 1 / Phase 2CompletedGilead Sciences722000-01-012021-08-19

Narrower conditions

Colorectal Neoplasms (3)  ·  Colonic Neoplasms (2)  ·  Rectal Neoplasms (1)

Broader conditions

Colonic Diseases (3)  ·  Digestive System Diseases (3)  ·  Digestive System Neoplasms (3)  ·  Gastrointestinal Diseases (3)  ·  Gastrointestinal Neoplasms (3)  ·  Intestinal Diseases (3)  ·  Intestinal Neoplasms (3)  ·  Neoplasms (3)  ·  Neoplasms by Site (3)  ·  Rectal Diseases (3)

Interventions

Cetuximab (2)  ·  IFL protocol (1)  ·  Irinotecan (1)  ·  encorafenib (1)  ·  enzastaurin (1)  ·  labetuzumab (1)

Sponsors

Eli Lilly and Company (1)  ·  Fondazione Policlinico Universitario Agostino Gemelli IRCCS (1)  ·  Gilead Sciences (1)

Countries

United States (2)  ·  Germany (1)  ·  Hungary (1)  ·  Italy (1)  ·  Sweden (1)  ·  Switzerland (1)

Top investigators

Maria Alessandra Calegari (1)  ·  William Wegener, MD (1)

NIH funding

2023 (1)